BioCryst Pharmaceuticals (BCRX) Q4 2025 earnings summary

Executive summary

• Achieved record 2025 revenue and first full-year profitability, driven by strong U.S. ORLADEYO growth, strategic portfolio expansion, and the acquisition of Astria Therapeutics, which added navenibart to the HAE pipeline.

• Completed sale of European ORLADEYO business in October 2025, focusing future growth on the U.S. market and pipeline assets.

• Maintained focus on rare disease innovation, disciplined capital allocation, and sustainable growth with high cash flow visibility.

• Positioned for durable revenue growth with new pediatric launches and late-stage pipeline assets, including FDA approval for ORLADEYO Pellets for ages 2–12.

• Positive interim results from navenibart Phase 3 and long-term trials; BCX17725 advancing for Netherton syndrome with Phase 1 data expected by year-end 2026.

Financial highlights

• Full year 2025 total revenues reached $874.8 million (GAAP), with non-GAAP total revenues of $592.9 million (+45% y-o-y); ORLADEYO net revenue was $601.8 million (+38% y-o-y; +43% y-o-y excluding Europe).

• Non-GAAP operating profit was $214.2 million (+198% y-o-y), with GAAP operating profit at $341 million; net income for 2025 was $263.9 million.

• Ended 2025 with $337.5 million in cash and investments; cash and investments pro forma at $279 million.

• Entered $400 million financing facility with Blackstone Life Sciences and drew a $400 million senior credit facility in January 2026.

• Paid off Pharmakon Term Loan ($323.7 million), reducing interest expense by 20% year-over-year.

Outlook and guidance

• 2026 ORLADEYO revenue guidance set at $625–$645 million; total revenue guidance at $635–$660 million.

• 2026 non-GAAP operating expenses expected between $450–$470 million, including Astria expenses.

• HAE franchise projected to generate double-digit revenue growth into the next decade, with $1B+ cash balance by 2029.

• R&D costs expected to rise in 2026 due to late-stage navenibart development, then decline post-completion.

• Committed to maintaining profitability and strong cash flow generation.